Abstract: Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.

Abstract: Presented herein are systems and methods that facilitate user review and uploading of files comprising medical images and associated metadata from a local computing device to a network-based image analysis and/or decision support platform. The systems and methods described herein allow image upload to be performed in a secure fashion that prevents the network-based platform from accessing sensitive data as it is prepared for upload. Prior to file upload, sensitive data elements are flagged and their values removed and/or masked. Notably, the approaches described herein provide intuitive graphical user interface (GUI) tools that allow a user, such as a medical practitioner or researcher, to review not only the images and metadata in the files that they plan to upload, but also to review and control the process by which sensitive data elements are removed and/masked, thereby confirming that all files are free of sensitive information prior to upload.

Abstract: Presented herein are systems and methods that provide for improved computer aided display and analysis of nuclear medicine images. In particular, the systems and methods described herein offer improved interactive adjustment of intensity windowing for display of nuclear medicine images. The interactive intensity window selection tools described herein utilize a nonlinear scaling function that maps user adjustments to positions of displayed indicator widgets on a scale to intensity window thresholds. The form of the scaling function increasingly magnifies user adjustments at the upper range of the scale, but remains linear at the lower end. The intensity windowing tools presented herein allow the user to adjust intensity thresholds over a full range of intensities encountered in an image, up to the maximum value, while still preserving fidelity in an important range that includes lower intensities.

Abstract: Presented herein are systems and methods that provide for improved computer aided display and analysis of nuclear medicine images. In particular, in certain embodiments, the systems and methods described herein provide improvements to several image processing steps used for automated analysis of bone scan images for assessing cancer status of a patient. For example, improved approaches for image segmentation, hotspot detection, automated classification of hotspots as representing metastases, and computation of risk indices such as bone scan index (BSI) values are provided.

Abstract: Presented herein are systems and methods that provide for automated analysis of medical images to determine a predicted disease status (e.g., prostate cancer status) and/or a value corresponding to predicted risk of the disease status for a subject. The approaches described herein leverage artificial intelligence (AI) to analyze intensities of voxels in a functional image, such as a PET image, and determine a risk and/or likelihood that a subject's disease, e.g., cancer, is aggressive. The approaches described herein can provide predictions of whether a subject that presents a localized disease has and/or will develop aggressive disease, such as metastatic cancer. These predictions are generated in a fully automated fashion and can be used alone, or in combination with other cancer diagnostic metrics (e.g., to corroborate predictions and assessments or highlight potential errors). As such, they represent a valuable tool in support of improved cancer diagnosis and treatment.

Abstract: Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.

Abstract: Provided herein are methods for assessing a subject with prostate cancer. The methods are also directed to or may further comprise treating the subject and/or making treatment management decisions based on the assessing.

Abstract: Presented herein are systems and methods that facilitate user review and uploading of files comprising medical images and associated metadata from a local computing device to a network-based image analysis and/or decision support platform. The systems and methods described herein allow image upload to be performed in a secure fashion that prevents the network-based platform from accessing sensitive data as it is prepared for upload. Prior to file upload, sensitive data elements are flagged and their values removed and/or masked. Notably, the approaches described herein provide intuitive graphical user interface (GUI) tools that allow a user, such as a medical practitioner or researcher, to review not only the images and metadata in the files that they plan to upload, but also to review and control the process by which sensitive data elements are removed and/masked, thereby confirming that all files are free of sensitive information prior to upload.

Abstract: Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.

Abstract: Provided herein are methods for assessing a subject with prostate cancer. The methods are also directed to or may further comprise treating the subject and/or making treatment management decisions based on the assessing.

Abstract: Provided herein are compositions and related methods for treating and/or identifying patients likely to respond to treatments for prostate cancer.

Abstract: Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and/or tissue. In certain embodiments, the accurate identification of one or more such volumes can be used to determine quantitative metrics that measure uptake of radiopharmaceuticals in particular organs and/or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and/or determine efficacy of a treatment modality.

Abstract: Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.

Abstract: Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.

Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.

Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.

Abstract: Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.

Abstract: The present invention provides a new forms of (R)-N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.

Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.

Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.